U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C31H25F3N2O4
Molecular Weight 546.5364
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SLX-4090

SMILES

COC1=C(C2=CC=C(C=C2)C(F)(F)F)C(=CC=C1)C(=O)NC3=CC4=C(CN(CC4)C(=O)OC5=CC=CC=C5)C=C3

InChI

InChIKey=AZUIUVJESCFSLJ-UHFFFAOYSA-N
InChI=1S/C31H25F3N2O4/c1-39-27-9-5-8-26(28(27)20-10-13-23(14-11-20)31(32,33)34)29(37)35-24-15-12-22-19-36(17-16-21(22)18-24)30(38)40-25-6-3-2-4-7-25/h2-15,18H,16-17,19H2,1H3,(H,35,37)

HIDE SMILES / InChI

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Microsomal triglyceride transfer protein large subunit
4
Target ID: P55157
Gene ID: 4547.0
Gene Symbol: MTTP
Target Organism: Homo sapiens (Human)
Inhibitor
8504
 8.0 nM [IC50]
Name Type Language
SLX-4090
Common Name English
KD-026
Preferred Name English
2(1H)-ISOQUINOLINECARBOXYLIC ACID, 3,4-DIHYDRO-6-(((6-METHOXY-4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-, PHENYL ESTER
Systematic Name English
PHENYL 6-((3-METHOXY-2-(4-(TRIFLUOROMETHYL)PHENYL)BENZOYL)AMINO)-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLATE
Systematic Name English
Code System Code Type Description
CAS
913541-47-6
Created by admin on Mon Mar 31 20:57:58 GMT 2025 , Edited by admin on Mon Mar 31 20:57:58 GMT 2025
PRIMARY
PUBCHEM
53497429
Created by admin on Mon Mar 31 20:57:58 GMT 2025 , Edited by admin on Mon Mar 31 20:57:58 GMT 2025
PRIMARY
FDA UNII
F84YQX13FV
Created by admin on Mon Mar 31 20:57:58 GMT 2025 , Edited by admin on Mon Mar 31 20:57:58 GMT 2025
PRIMARY
CLINICAL_TRIALS.GOV
SLX-4090
Created by admin on Mon Mar 31 20:57:58 GMT 2025 , Edited by admin on Mon Mar 31 20:57:58 GMT 2025
PRIMARY Funding Source - FDA OOPDPurpose: This study is being done to find out whether an investigational (not approved by FDA ) drug called SLx-4090 or Orlistat (FDA approved medication for weight loss) when given alone or in combination can treat the high blood fat (elevated triglycerides)levels found in the condition Type 1 Hyperlipoproteinemia (T1HLP) better or more safely than low fat diet alone, the current standard medical care.It is also not clear whether Orlistat, that is FDA approved for weight loss, is effective in lowering blood fat levels in patients with Type 1 hyperlipoproteinemia (T1HLP). The researchers are interested in learning whether any one of these drugs when given alone or in combination is more effective and safe in treating T1HLP.
DRUG BANK
DB05678
Created by admin on Mon Mar 31 20:57:58 GMT 2025 , Edited by admin on Mon Mar 31 20:57:58 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of SLX-4090
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966